From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus

Andrea J. Dooley, Nice Shindo, Barbara Taggart, Jewn Giew Park, Yuan-Ping Pang

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem. 2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc. 2002, 1 220], is limited by a known challenge in crystallographically determining flexible regions of proteins. This approach has not been able to identify active inhibitors of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) using solely the crystal structures of a SARS-CoV cysteine proteinase with a flexible loop in the active site [Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190; Jenwitheesuk, E.; Samudrala, R. Bioorg. Med. Chem. Lett. 2003, 13, 3989; Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. Biochem. Biophys. Res. Commun. 2004, 321, 370; Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K. Anal. Biochem. 2005, 337, 262; Du, Q.; Wang, S.; Zhu, Y.; Wei, D.; Guo, H. Peptides 2004, 25, 1857; Lee, V.; Wittayanarakul, K.; Remsungenen, T.; Parasuk, V.; Sompornpisut, P. Science (Asia) 2003, 29, 181; Toney, J.; Navas-Martin, S.; Weiss, S.; Koeller, A. J. Med. Chem. 2004, 47, 1079; Zhang, X. W.; Yap, Y. L. Bioorg. Med. Chem. 2004, 12, 2517]. This article demonstrates a genome-to-drug-lead approach that uses terascale computing to model flexible regions of proteins, thus permitting the utilization of genetic information to identify drug leads expeditiously. A small-molecule inhibitor of SARS-CoV, exhibiting an effective concentration (EC50) of 23 μM in cell-based assays, was identified through virtual screening against a computer-predicted model of the cysteine proteinase. Screening against two crystal structures of the same proteinase failed to identify the 23-μM inhibitor. This study suggests that terascale computing can complement crystallography, broaden the scope of virtual screening, and accelerate the development of therapeutics to treat emerging infectious diseases such as SARS and Bird Flu.

Original languageEnglish (US)
Pages (from-to)830-833
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume16
Issue number4
DOIs
StatePublished - Feb 15 2006

Fingerprint

SARS Virus
Viruses
Severe Acute Respiratory Syndrome
Coronavirus
Screening
Genes
Genome
Molecules
Cysteine Proteases
Pharmaceutical Preparations
Crystal structure
Emerging Communicable Diseases
Crystallography
Birds
Computer Simulation
Assays
Catalytic Domain
Proteins
Peptide Hydrolases
Peptides

Keywords

  • Anti-SARS agents
  • Antiviral agents
  • Chemical databases
  • Docking
  • Drug lead identification
  • In silico screening
  • Small-molecule inhibitor leads

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

From genome to drug lead : Identification of a small-molecule inhibitor of the SARS virus. / Dooley, Andrea J.; Shindo, Nice; Taggart, Barbara; Park, Jewn Giew; Pang, Yuan-Ping.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 16, No. 4, 15.02.2006, p. 830-833.

Research output: Contribution to journalArticle

Dooley, Andrea J. ; Shindo, Nice ; Taggart, Barbara ; Park, Jewn Giew ; Pang, Yuan-Ping. / From genome to drug lead : Identification of a small-molecule inhibitor of the SARS virus. In: Bioorganic and Medicinal Chemistry Letters. 2006 ; Vol. 16, No. 4. pp. 830-833.
@article{a714c451587e455ab2d9a47b7bd640a8,
title = "From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus",
abstract = "Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem. 2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc. 2002, 1 220], is limited by a known challenge in crystallographically determining flexible regions of proteins. This approach has not been able to identify active inhibitors of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) using solely the crystal structures of a SARS-CoV cysteine proteinase with a flexible loop in the active site [Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190; Jenwitheesuk, E.; Samudrala, R. Bioorg. Med. Chem. Lett. 2003, 13, 3989; Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. Biochem. Biophys. Res. Commun. 2004, 321, 370; Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K. Anal. Biochem. 2005, 337, 262; Du, Q.; Wang, S.; Zhu, Y.; Wei, D.; Guo, H. Peptides 2004, 25, 1857; Lee, V.; Wittayanarakul, K.; Remsungenen, T.; Parasuk, V.; Sompornpisut, P. Science (Asia) 2003, 29, 181; Toney, J.; Navas-Martin, S.; Weiss, S.; Koeller, A. J. Med. Chem. 2004, 47, 1079; Zhang, X. W.; Yap, Y. L. Bioorg. Med. Chem. 2004, 12, 2517]. This article demonstrates a genome-to-drug-lead approach that uses terascale computing to model flexible regions of proteins, thus permitting the utilization of genetic information to identify drug leads expeditiously. A small-molecule inhibitor of SARS-CoV, exhibiting an effective concentration (EC50) of 23 μM in cell-based assays, was identified through virtual screening against a computer-predicted model of the cysteine proteinase. Screening against two crystal structures of the same proteinase failed to identify the 23-μM inhibitor. This study suggests that terascale computing can complement crystallography, broaden the scope of virtual screening, and accelerate the development of therapeutics to treat emerging infectious diseases such as SARS and Bird Flu.",
keywords = "Anti-SARS agents, Antiviral agents, Chemical databases, Docking, Drug lead identification, In silico screening, Small-molecule inhibitor leads",
author = "Dooley, {Andrea J.} and Nice Shindo and Barbara Taggart and Park, {Jewn Giew} and Yuan-Ping Pang",
year = "2006",
month = "2",
day = "15",
doi = "10.1016/j.bmcl.2005.11.018",
language = "English (US)",
volume = "16",
pages = "830--833",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - From genome to drug lead

T2 - Identification of a small-molecule inhibitor of the SARS virus

AU - Dooley, Andrea J.

AU - Shindo, Nice

AU - Taggart, Barbara

AU - Park, Jewn Giew

AU - Pang, Yuan-Ping

PY - 2006/2/15

Y1 - 2006/2/15

N2 - Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem. 2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc. 2002, 1 220], is limited by a known challenge in crystallographically determining flexible regions of proteins. This approach has not been able to identify active inhibitors of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) using solely the crystal structures of a SARS-CoV cysteine proteinase with a flexible loop in the active site [Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190; Jenwitheesuk, E.; Samudrala, R. Bioorg. Med. Chem. Lett. 2003, 13, 3989; Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. Biochem. Biophys. Res. Commun. 2004, 321, 370; Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K. Anal. Biochem. 2005, 337, 262; Du, Q.; Wang, S.; Zhu, Y.; Wei, D.; Guo, H. Peptides 2004, 25, 1857; Lee, V.; Wittayanarakul, K.; Remsungenen, T.; Parasuk, V.; Sompornpisut, P. Science (Asia) 2003, 29, 181; Toney, J.; Navas-Martin, S.; Weiss, S.; Koeller, A. J. Med. Chem. 2004, 47, 1079; Zhang, X. W.; Yap, Y. L. Bioorg. Med. Chem. 2004, 12, 2517]. This article demonstrates a genome-to-drug-lead approach that uses terascale computing to model flexible regions of proteins, thus permitting the utilization of genetic information to identify drug leads expeditiously. A small-molecule inhibitor of SARS-CoV, exhibiting an effective concentration (EC50) of 23 μM in cell-based assays, was identified through virtual screening against a computer-predicted model of the cysteine proteinase. Screening against two crystal structures of the same proteinase failed to identify the 23-μM inhibitor. This study suggests that terascale computing can complement crystallography, broaden the scope of virtual screening, and accelerate the development of therapeutics to treat emerging infectious diseases such as SARS and Bird Flu.

AB - Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem. 2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc. 2002, 1 220], is limited by a known challenge in crystallographically determining flexible regions of proteins. This approach has not been able to identify active inhibitors of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) using solely the crystal structures of a SARS-CoV cysteine proteinase with a flexible loop in the active site [Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190; Jenwitheesuk, E.; Samudrala, R. Bioorg. Med. Chem. Lett. 2003, 13, 3989; Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. Biochem. Biophys. Res. Commun. 2004, 321, 370; Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K. Anal. Biochem. 2005, 337, 262; Du, Q.; Wang, S.; Zhu, Y.; Wei, D.; Guo, H. Peptides 2004, 25, 1857; Lee, V.; Wittayanarakul, K.; Remsungenen, T.; Parasuk, V.; Sompornpisut, P. Science (Asia) 2003, 29, 181; Toney, J.; Navas-Martin, S.; Weiss, S.; Koeller, A. J. Med. Chem. 2004, 47, 1079; Zhang, X. W.; Yap, Y. L. Bioorg. Med. Chem. 2004, 12, 2517]. This article demonstrates a genome-to-drug-lead approach that uses terascale computing to model flexible regions of proteins, thus permitting the utilization of genetic information to identify drug leads expeditiously. A small-molecule inhibitor of SARS-CoV, exhibiting an effective concentration (EC50) of 23 μM in cell-based assays, was identified through virtual screening against a computer-predicted model of the cysteine proteinase. Screening against two crystal structures of the same proteinase failed to identify the 23-μM inhibitor. This study suggests that terascale computing can complement crystallography, broaden the scope of virtual screening, and accelerate the development of therapeutics to treat emerging infectious diseases such as SARS and Bird Flu.

KW - Anti-SARS agents

KW - Antiviral agents

KW - Chemical databases

KW - Docking

KW - Drug lead identification

KW - In silico screening

KW - Small-molecule inhibitor leads

UR - http://www.scopus.com/inward/record.url?scp=30344480804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344480804&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2005.11.018

DO - 10.1016/j.bmcl.2005.11.018

M3 - Article

C2 - 16325400

AN - SCOPUS:30344480804

VL - 16

SP - 830

EP - 833

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 4

ER -